Results 151 to 160 of about 226,532 (174)
[Chinese guidelines on the treatment of hemophilia (2025)]. [PDF]
Zhonghua Xue Ye Xue Za ZhiThrombosis and Hemostasis Group +3 more
europepmc +1 more source
[Single-center clinical study of upadacitinib in children with refractory inflammatory bowel disease]. [PDF]
Zhongguo Dang Dai Er Ke Za ZhiCheng Q +5 more
europepmc +1 more source
[Indications of biological treatment in patients with chronic rhinosinusitis with nasal polyps]. [PDF]
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za ZhiWang C, Zhu D, Zhang L.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
非小细胞肺癌新辅助免疫治疗的研究进展、获益人群、治疗周期和疗效预测
Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2022免疫检查点抑制剂（immune checkpoint inhibitors, ICIs）的出现极大程度上改变了非小细胞肺癌（non-small cell lung cancer, NSCLC）患者的治疗前景，术前新辅助免疫治疗方案作为一种有效、安全的治疗方案逐渐受到重视。然而，新辅助免疫治疗方案相关的研究起步时间较晚，研究成果相对较少且主要集中于样本量较小的Ⅰ期、Ⅱ期研究，治疗方案本身存在也许多尚不明确的地方，在获益人群的筛选、治疗周期的选择和疗效预测等方面也尚未达成广泛的共识 ...
Jingbin Ji +3 more
semanticscholar +1 more source
Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2022
肿瘤免疫疗法在当前癌症治疗领域中愈来愈受瞩目，相关研究也层出不穷。对于非小细胞肺癌（non-small cell lung cancer, NSCLC）患者来说，近些年来，以程序性死亡受体1（programmed cell death 1, PD-1）/程序性死亡配体1（programmed cell death ligand 1, PD-L1）免疫抑制剂为代表的免疫检查点抑制剂（immune checkpoint inhibitors, ICIs）已经成为治疗恶性肿瘤的一种最具前景的治疗方案 ...
Nan Wang, Xia Song
semanticscholar +1 more source
肿瘤免疫疗法在当前癌症治疗领域中愈来愈受瞩目，相关研究也层出不穷。对于非小细胞肺癌（non-small cell lung cancer, NSCLC）患者来说，近些年来，以程序性死亡受体1（programmed cell death 1, PD-1）/程序性死亡配体1（programmed cell death ligand 1, PD-L1）免疫抑制剂为代表的免疫检查点抑制剂（immune checkpoint inhibitors, ICIs）已经成为治疗恶性肿瘤的一种最具前景的治疗方案 ...
Nan Wang, Xia Song
semanticscholar +1 more source